Lee, Matilda Xinwei
Wong, Andrea L. A.
Ow, Samuel
Sundar, Raghav
Tan, David S. P.
Soo, Ross A.
Chee, Cheng Ean
Lim, Joline S. J.
Yong, Wei Peng
Lim, Siew Eng
Goh, Boon Cher
Wang, Lingzhi
Lee, Soo Chin http://orcid.org/0000-0002-5835-6419
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
https://doi.org/10.1007/s11523-022-00867-0
Funding for this research was provided by:
National Medical Research Council (NMRC/CSA-SI/0004/2015, NRMC/CSA/015/2009, NMRC/CG/012/2013)
Article History
Accepted: 29 January 2022
First Online: 23 February 2022
Declarations
:
: This study was funded by research grants from the Singapore Ministry of Health’s National Medical Research Council under its Clinician Scientist Awards [Grant numbers: NMRC/CSA-SI/0004/2015 and NRMC/CSA/015/2009] and the National University Cancer Institute, Singapore’s Centre Grant [Grant number: NMRC/CG/012/2013]. Varlitinib was kindly provided by ASLAN Pharmaceuticals Ltd (Singapore) through a research collaboration.
: Andrea Wong has received honoraria from Pfizer, Novartis, and Eisai; and has advisory activity with Otsuka. Samuel Ow has received honoraria from Pfizer, AstraZeneca, Eli Lilly, Novartis, and Roche. Raghav Sundar has received honoraria from Bristol-Myers Squibb, Lilly, Roche, Taiho, Astra Zeneca, DKSH, and MSD; has advisory activity with Bristol-Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD, and AstraZeneca; received research funding from MSD and Paxman Coolers; and has received travel grants from AstraZeneca, Eisai, Roche, and Taiho Pharmaceutical. David Tan has received honoraria and travel support from AstraZeneca, Novartis, Roche, Merck Serono, MSD, Bayer, Genmab, Takeda, Eisai, and Clovis; has advisory activity with Astra Zeneca, MSD, Roche, Bayer, Genmab, Tessa Therapeutics, and Eisai; has received research funding from Astra Zeneca, Karyopharm Therapeutics, Bayer, Roche (Foundation Medicine), National Medical Research Council Singapore, Pangestu Family Foundation Gynaecological Cancer Research Fund, and Cancer Science Institute Singapore; and has stock ownership with Asian Microbiome Library (AMiLi). Ross Soo has advisory activity with Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, and Yuhan; and has received research funding from AstraZeneca and Boehringer Ingelheim. Joline Lim has advisory activity with Pfizer and Novartis; has received research funding from Synthon; and has received conference support from Novartis, Pfizer, and AstraZeneca. Wei Peng Yong has advisory activity with Abbvie, Amgen, AstraZeneca, BMS, Ipsen, Novartis, and MSD; and has received support on the speaker bureaus for Bayer, Eisai, Lilly, Sanofi, and Taiho. Boon Cher Goh has received research funding from MSD, Adagene, Bayer Healthcare, and Alx Oncology; has advisory activity with Adagene, MSD, and Novartis; and has stock ownership with Merus Therapeutics and Gilead Sciences. Soo Chin Lee has advisory activity with Pfizer, Novartis, Astra Zeneca, ACT Genomics, Eli Lilly, MSD, and Roche; has received research funding from Pfizer, Eisai, Taiho, ACT Genomics, Bayer, and Karyopharm; and has received conference support from Amgen, Pfizer, and Roche. Matilda Lee, Siew Eng Lim, and Ling Zhi Wang declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.
: This study was approved by the National Healthcare Group Domain Specific Review Board prior to commencement. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.
: Consent was obtained from all individual participants included in the study.
: Not applicable.
: Not applicable.
: Soo Chin Lee and Boon Cher Goh contributed to the study conception and design. Matilda Lee, Andrea Wong, Raghav Sundar, David Tan, Ross Soo, Cheng Ean Chee, Joline Lim, Wei Peng Yong, Siew Eng Lim, Boon Cher Goh, and Soo Chin Lee recruited patients into the trial and contributed to data collection. Lingzhi Wang performed the paclitaxel pharmacokinetic analysis. Matilda Lee, Lingzhi Wang and Soo Chin Lee performed the data analysis and data interpretation. The original draft of the manuscript was prepared by Matilda Lee and Soo Chin Lee, and all authors have commented on, read, and approved the final manuscript.